In Vivo Study of a Newly Synthesized Chromen-4-One Derivative as an Antitumor Agent Against HCC

Résumé

Abstract Background: Chromenes are a wide group of natural compounds that can be synthesized chemically. The chromen-4-one nucleus acts as a skeleton for varieties of additional active groups that makes the chromenes activity varies between antioxidant and anti-inflammatory agents. In the present study, a newly synthesized chromene compound exhibits different behavior other than anti-inflammatory and antioxidant activities that it is the first time that a member of chromen-4-one compound can control the cancer progress. Inflammation is the first step in tumor development where the severity grade can potentiate tumor growth and progression. In many tumors pro-inflammatory genes record high expression level such as tumor necrosis factor (TNF-α) and vascular endothelial growth factors (VEGF). These pro-inflammatory factors act as rate limiting steps in tumor initiation and controlling its expression acts as an early therapeutic way to control the tumor proliferation. The chromone derivatives have biological activities such as anti-inflammatory and antitumor activity. Methods: In the present study a new chromene derivative (Ch) was studied against HCC induced by diethylnitrosamine (DEN) in rats. Results: The treatment strategy Ch compound is to down regulate pro-inflammatory gene expression of early genes as TNF-α as well as VEGF and subsequently controls other factors such as p53, Cyt C and MMP-9. Also, retrieve the balance between Bcl2 and Bax proteins in DEN induced HCC in rats. Conclusion: The ability to control the primary initiators of HCC offers the new Ch derivative an antitumor activity and encourages further researches to follow and monitor its effect on the molecular level.

Citer ce document

Accès au document

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0